
07/06/2022
The US Food and Drug Administration (FDA) has approved the first generic versions of Novartis multiple sclerosis drug Gilenya (fingolimod).
Generic fingolimod applications by HEC Pharm, Biocon, and Sun Pharmaceutical Industries secured the FDA authorization to treat adults with relapsing forms of multiple sclerosis.
Multiple sclerosis is an inflammatory, autoimmune disease that affects the central nervous system and disturbs communication between the brain and other body parts.